Detail for Itraconazole
Basic Information
DrugID 58
DrugName Itraconazole
DrugDetail One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

http://www.drugbank.ca/drugs/DB01167

http://en.wikipedia.org/wiki/Itraconazole

Indication For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

http://www.drugbank.ca/drugs/DB01167

Structure Click to see the orginal picture.
Interaction
Drug Name PMIDLink Reference
6-amino-2-n-pentylthiobenzothiazole M��ckov�� M, Bujd��kov�� H, Kuchta T. (2000) Synergy between 6-amino-2-n-pentylthiobenzothiazole and ergosterol biosynthesis-inhibiting antimycotics against Candida albicans in vitro. Int J Antimicrob Agents. 15(2):153-4.
Amiodarone Guo Q, Sun S, Li Y, Yu J, Shi C. (2008) In vitro interactions between azoles and amiodarone against clinical Candida albicans. Int J Antimicrob Agents. 31(1):88-90.
Amiodarone Afeltra J, Vitale RG, Mouton JW, Verweij PE. (2004) Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds andagainst clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother. 48(4):1335-43.
Anidulafungin Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. (2005) In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother. 49(8):3572-4.
Anidulafungin Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. (2006) In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents. 27(2):174-7.
Bupivacaine Rodrigues AG, Araujo R, Pina-Vaz C. (2006) Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus. Int J Antimicrob Agents. 27(4):339-43.
Caspofungin Shalit I, Shadkchan Y, Samra Z, Osherov N. (2003) In vitro synergy of caspofungin andagainst Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother. 47(4):1416-8.
Cyclosporine Dannaoui E, Schwarz P, Lortholary O. (2009) In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother. 53(8):3549-51.
Dodecapeptide Duggineni S, Srivastava G, Kundu B, Kumar M, Chaturvedi AK, Shukla PK. (2007) A novel dodecapeptide from a combinatorial synthetic library exhibits potent antifungal activity and synergy with standard antimycotic agents. Int J Antimicrob Agents. 29(1):73-8.
Ethambutol Cordeiro Rde A, Brilhante RS, Rocha MF, Medrano DJ, Monteiro AJ, Tavares JL, de Lima RA, de Camargo ZP, Sidrim JJ. (2009) In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii. Int J Antimicrob Agents. 34(3):278-80.
Flucytosine Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 47(10):3361-4.
Fluvastatin Chin NX, Weitzman I, Della-Latta P. (1997) In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole andagainst Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother. 41(4):850-2.
Isoniazid Cordeiro Rde A, Brilhante RS, Rocha MF, Medrano DJ, Monteiro AJ, Tavares JL, de Lima RA, de Camargo ZP, Sidrim JJ. (2009) In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii. Int J Antimicrob Agents. 34(3):278-80.
Lansoprazole Afeltra J, Vitale RG, Mouton JW, Verweij PE. (2004) Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds andagainst clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother. 48(4):1335-43.
Lidocaine Rodrigues AG, Araujo R, Pina-Vaz C. (2006) Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus. Int J Antimicrob Agents. 27(4):339-43.
Micafungin Ru��z-Cendoya M, Rodriguez MM, Marin�� M, Pastor FJ, Guarro J. (2008) In vitro interactions ofand micafungin against clinically important filamentous fungi. Int J Antimicrob Agents. 32(5):418-20.
Micafungin Marin�� M, Serena C, Pastor J, Quind��s G, Carrillo AJ, Guarro J. (2007) In vitro activity of micafungin combined withagainst Candida spp. Int J Antimicrob Agents. 30(5):463-5.
Nifedipine Afeltra J, Vitale RG, Mouton JW, Verweij PE. (2004) Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds andagainst clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother. 48(4):1335-43.
Nikkomycin Z Li RK, Rinaldi MG. (1999) In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother. 43(6):1401-5.
Nikkomycin X Hector RF, Schaller K. (1992) Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 36(6):1284-9.
Nikkomycin Z Hector RF, Schaller K. (1992) Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 36(6):1284-9.
Pyrazinamide Cordeiro Rde A, Brilhante RS, Rocha MF, Medrano DJ, Monteiro AJ, Tavares JL, de Lima RA, de Camargo ZP, Sidrim JJ. (2009) In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii. Int J Antimicrob Agents. 34(3):278-80.
Terbinafine Ortoneda M, Capilla J, Pastor FJ, Pujol I, Yustes C, Serena C, Guarro J. (2004) In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother. 48(7):2727-9.
Terbinafine C��rdoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG.. (2008) In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 31(2):171-4.
Terbinafine Dunn JJ, Billetdeaux E, Skodack-Jones L, Carroll KC. (2003) Evaluation of three Copan viral transport systems for the recovery of cultivatable, clinical virus isolates. Diagn Microbiol Infect Dis. 45(3):191-7.
Terbinafine Meletiadis J, Mouton JW, Meis JF, Verweij PE. (2003) In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 47(1):106-17.
Terbinafine Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE. (2000) In vitro interaction of terbinafine withagainst clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother. 44(2):470-2.
Terbinafine Te Dorsthorst DT, Verweij PE, Meis JF, Punt NC, Mouton JW. (2002) Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother. 46(3):702-7.
Voriconazole Garcia-Effron G, Mellado E, Gomez-Lopez A, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. (2005) Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob Agents Chemother. 49(5):2119-21.
Amphotericin B Denning D.W., Hanson L.H., Perlman A.M., Stevens D.A. (1992) Invitro susceptibility and synergy studies of aspergillus species to conventional and new agents. Diagnostic Microbiology and Infectious Disease 15:21-34.
Flucytosine Barchiesi F., Gallo D., Caselli F., Di Francesco L.F., Arzeni D., Giacometti A., Scalise G. (1999) In-vitro interactions ofwith flucytosine against clinical isolates of Cryptococcus neoformans. Journal of Antimicrobial Chemotherapy 44:65-70.
Micafungin Ruiz-Cendoya M., Rodriguez M.M., Marine M., Pastor F.J., Guarro J. (2008) In vitro interactions ofand micafungin against clinically important filamentous fungi. International Journal of Antimicrobial Agents 32:418-420. DOI: 10.1016/j.ijantimicag.2008.05.015.
Cyclosporine Dannaoui E., Schwarz P., Lortholary O. (2009) In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes. Antimicrobial Agents and Chemotherapy 53:3549-3551. DOI: 10.1128/aac.00184-09
Tacrolimus Dannaoui E., Schwarz P., Lortholary O. (2009) In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes. Antimicrobial Agents and Chemotherapy 53:3549-3551. DOI: 10.1128/aac.00184-09
Rapamycin Dannaoui E., Schwarz P., Lortholary O. (2009) In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes. Antimicrobial Agents and Chemotherapy 53:3549-3551. DOI: 10.1128/aac.00184-09
Terbinafine Barchiesi F., Gallo D., Caselli F., Di Francesco L.F., Arzeni D., Giacometti A., Scalise G. (1999) In-vitro interactions ofwith flucytosine against clinical isolates of Cryptococcus neoformans. Journal of Antimicrobial Chemotherapy 44:65-70.
Cyclosporine A Li Y., Sun S.J., Guo Q.J., Ma L., Shi C.W., Su L.Q., Li H.J. (2008) In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. Journal of Antimicrobial Chemotherapy 61:577-585. DOI: 10.1093/jac/dkm493.
FK506 Sun S., Li Y., Guo Q.J., Shi C.W., Yu J.L., Ma L. (2008) In vitro interactions between tacrolimus and Azoles against Candida albicans determined by different methods. Antimicrobial Agents and Chemotherapy 52:409-417. DOI: 10.1128/aac.01070-07.
Target
PathWay
PathWay Name Path Picture
Steroid biosynthesis - Reference pathway (KO)